Hematology/Oncology · San Francisco, CA
NPI
1578632980
Since 2006
Specialty
Hematology/Oncology
Code 174400000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2100 Webster St Ste 225
San Francisco, CA, 94115
Phone (415) 923-3012
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.9M
130,844 services
Medicare patients, 2024
552
Average age 77
Drug cost, 2024
$11.3M
2,119 prescriptions
Company payments, 2025
$2,456
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bertrand Y Tuan was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 17,043 times for 37 patients. In total Bertrand Y Tuan billed 130,844 services in 116 codes, and Medicare paid $2.9M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 17,043 | 37 | $2.31 | $39K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 14,280 | 16 | $0.28 | $4,036 |
| J0897 Injection, denosumab, 1 mg | Office | 8,780 | 34 | $20.69 | $182K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,300 | 13 | $44.83 | $327K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 4,871 | 11 | $39.01 | $190K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 2,407 | 11 | $0.12 | $281 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,706 | 48 | $0.09 | $154 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,311 | 42 | $0.70 | $922 |
| 85025 Blood Count | Office | 946 | 255 | $7.61 | $7,199 |
| 99214 Office E&M - Established | Office | 845 | 412 | $110.49 | $93K |
| J9190 Injection, fluorouracil, 500 mg | Office | 600 | 15 | $2.37 | $1,421 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 446 | 12 | $3.34 | $1,491 |
| 96372 Injection Administration | Office | 402 | 106 | $13.57 | $5,455 |
| 96413 Chemotherapy Administration | Office | 323 | 81 | $135.41 | $44K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 206 | 13 | $111.73 | $23K |
By year: 2022 $2.1M for 105,762 services; 2023 $1.9M for 96,967 services; 2024 $2.9M for 130,844 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 946 | 255 | $7.61 | $7,199 |
Medicare prescription drug claims, 2024
In 2024, the drug Bertrand Y Tuan prescribed most often to Medicare patients was Hydroxyurea, with 142 prescriptions and refills. In total Bertrand Y Tuan wrote 2,119 Medicare prescriptions that cost $11.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 142 | 260 | 31 | $1,619 |
| Aranesp Darbepoetin Alfa In Polysorbat | 137 | 137 | 30 | $282K |
| Eliquis Apixaban | 122 | 164 | 22 | $93K |
| Calquence Acalabrutinib Maleate | 80 | 80 | Under 11 | $1.2M |
| Acyclovir Generic | 76 | 110 | 16 | $1,360 |
| Nplate Romiplostim | 71 | 71 | Under 11 | $472K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 58 | 58 | Under 11 | $606K |
| Reblozyl Luspatercept-Aamt | 53 | 54 | Under 11 | $808K |
| Xarelto Rivaroxaban | 48 | 80 | Under 11 | $45K |
| Imatinib Mesylate Generic | 45 | 45 | Under 11 | $26K |
| Revlimid Lenalidomide | 41 | 41 | Under 11 | $736K |
| Brukinsa Zanubrutinib | 39 | 39 | Under 11 | $378K |
| Nubeqa Darolutamide | 38 | 38 | Under 11 | $321K |
| Imbruvica Ibrutinib | 37 | 37 | Under 11 | $588K |
| Pomalyst Pomalidomide | 37 | 37 | Under 11 | $827K |
Brand drugs: 1,254 claims; generic drugs: - claims; opioid claims: 66.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bertrand Y Tuan $2,456 ($2,456 in general payments such as food, travel and fees) from 43 companies. The largest payer was Daiichi Sankyo Inc. with $260.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 7 | $260 |
| Celgene Corporation BMY | 11 | $255 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $152 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $135 |
| Pfizer Inc. PFE | 4 | $123 |
| Abbvie Inc. ABBV | 4 | $103 |
| Astellas Pharma US Inc 4503.T | 3 | $75.38 |
| Coherus Oncology, Inc. CHRS | 2 | $73.81 |
| Taiho Oncology, Inc. 4578.T | 2 | $71.21 |
| Merck Sharp & Dohme LLC MRK | 2 | $68.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.